QIAGEN

QIAGEN Advances NGS Efficiency with QIAseq Normalizer Kits for DNA Library Optimization

(IN BRIEF) QIAGEN has launched the QIAseq Normalizer Kits, a new solution for researchers to efficiently pool different DNA libraries…

10 months ago

QIAGEN and Servier Collaborate to Develop Diagnostic Test for Hard-to-Treat Blood Cancer

(IN BRIEF) QIAGEN has entered into a partnership with global pharmaceutical group, Servier, to develop a companion diagnostic test for…

1 year ago

QIAGEN, der führende Anbieter von molekularen Sample-to-Insight-Lösungen, kündigt eine bedeutende Erweiterung seines Angebots an digitalen PCR (dPCR)-Assays an

13 neue Kits und Tests ermöglichen die Quantifizierung von AAV-Titern und restlicher Wirtszell-DNA in der Zell- und Gentherapie Custom Assay…

2 years ago

QIAGEN gibt neue Meilensteine für seinen Tuberkulose-Test QuantiFERON bekannt

HILDEN, Deutschland, GERMANTOWN, Maryland (USA), und SHANGHAI, China, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA),…

2 years ago

QIAGEN annonce de nouvelles étapes pour son test de tuberculose QuantiFERON

(COMMUNIQUÉ DE PRESSE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE : QGEN ; Frankfurt…

2 years ago

QIAGEN announces new milestones for its QuantiFERON tuberculosis test

(PRESS RELEASE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN N.V. (NYSE: QGEN; Frankfurt…

2 years ago

QIAGEN announces two new collaborations for its dPCR platform QIAcuity: Atila BioSystems and Actome

Expanding range of applications for growing base of QIAcuity digital PCR instruments Two new collaborations: Atila BioSystems expands menu to…

2 years ago

QIAGEN appoints Dr. Toralf Haag as a member of the Supervisory Board and the Audit Committee

(PRESS RELEASE) VENLO, the Netherlands, 8-Jan-2021 — /EuropaWire/ — QIAGEN announces the appointment of Dr. Toralf Haag as a member…

3 years ago

QIAGEN Ergebnisse einer neuen Evaluierung im Bereich der Frauengesundheit die hohe Genauigkeit seiner Bioinformatik-Lösungen untermauern

Ergebnisse der Evaluierung der QCI-Plattform zur Interpretation klinisch relevanter Genvarianten werden auf der ASHG 2017 von Counsyl vorgestellt Orlando, Florida…

7 years ago

France’s Ministry of Health and Social Affairs approves reimbursement for QIAGEN’s QuantiFERON-TB® Gold Plus latent tuberculosis test

Gold-standard test for latent tuberculosis infection will be covered by national health insurance Hilden, Germany, and Paris, France, 23-Jun-2017 —…

7 years ago

DiaSorin, QIAGEN to develop new tests for DiaSorin’s LIAISON family of analyzers

Saluggia, Italy; Hilden, Germany, and Germantown, Maryland, USA, 23-Jun-2017 — /EuropaWire/ — DiaSorin (FTSE Italy Mid Cap: DIA) and QIAGEN…

7 years ago

U.S. FDA premarket approval for QIAGEN’s automated artus® CMV QS-RGQ MDx kit for use on its QIAsymphony platform

High-throughput application of artus CMV QS-RGQ MDx Kit on QIAsymphony streamlines critical and frequently performed viral infection test for transplant…

7 years ago

QIAGEN receives worldwide license from The Johns Hopkins University for biomarkers for immune-oncology therapies in cancer treatment

Option to add new biomarkers for microsatellite instability (MSI) and mismatch repair (MMR) to QIAGEN’ s NGS panels Hilden, Germany,…

7 years ago

Bristol-Myers Squibb and QIAGEN to explore NGS technology to develop GEPs for I-O therapies in cancer treatment

NEW YORK and HILDEN, Germany, 06-Jun-2017 — /EuropaWire/ — Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN(NASDAQ: QGEN; Frankfurt Prime Standard: QIA)…

7 years ago

Evaluation affirms the performance of the QIAGEN’s GeneReader NGS System in detecting gene variants known to be clinically relevant in colorectal cancer

World’s first complete Sample to Insight NGS solution proves equal or better compared with other sequencing workflows and alternative technologies…

8 years ago

QIAGEN N.V. released Q2 and H1 2013 results and announced new share repurchase program

Q2 2013 results: Adjusted net sales of $316.4 million (+3% CER) on growth in all regions; adjusted operating income of…

11 years ago